Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pevonedistat + Temozolomide + Irinotecan in Pediatric Solid Tumors
NCT03323034Phase 1Completed
- Sponsor
- Children's Oncology Group
- Start
- Jan 2018
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pevonedistat in solid tumor, central nervous system tumor and lymphoma, sponsored by Children's Oncology Group. Primary endpoints: Maximum Tolerated Dose and/or Recommended Phase 2 Dose up to 28 days, Number of Participants With Grade 3 or Greater Toxicities and 5 more. Started Jan 2018; status: completed.
02
Drugs
pevonedistat
03
Conditions
solid tumorcentral nervous system tumorlymphoma
Beyond the preview
Go deeper on NCT03323034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03323034.